Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/176940
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Alternative oxidase inhibitors: Mitochondrion-targeting as a strategy for new drugs against pathogenic parasites and fungi

AutorEbiloma, Godwin U.; Balogun, Emmanuel O.; Cueto-Díaz, Eduardo J. CSIC ORCID; Koning, Harry P. de; Dardonville, Christophe CSIC ORCID
Palabras claveStructure‐aided drug design
Lipophilic cation
Trypanosome alternative oxidase
Triphenylphosphonium
Synthetic strategies
Ascofuranone
Structure‐activity relationship
Salicylhydroxamic acid analogues
Mitochondrial targeting
Fecha de publicación2019
EditorJohn Wiley & Sons
CitaciónMedicinal Research Reviews : 1-50 (2019)
ResumenThe alternative oxidase (AOX) is a ubiquitous terminal oxidase of plants and many fungi, catalyzing the four-electron reduction of oxygen to water alongside the cytochrome-based electron transfer chain. Unlike the classical electron transfer chain, however, the activity of AOX does not generate adenosine triphosphate but has functions such as thermogenesis and stress response. As it lacks a mammalian counterpart, it has been investigated intensely in pathogenic fungi. However, it is in African trypanosomes, which lack cytochrome-based respiration in their infective stages, that trypanosome alternative oxidase (TAO) plays the central and essential role in their energy metabolism. TAO was validated as a drug target decades ago and among the first inhibitors to be identified was salicylhydroxamic acid (SHAM), which produced the expected trypanocidal effects, especially when potentiated by coadministration with glycerol to inhibit anaerobic energy metabolism as well. However, the efficacy of this combination was too low to be of practical clinical use. The antibiotic ascofuranone (AF) proved a much stronger TAO inhibitor and was able to cure Trypanosoma vivax infections in mice without glycerol and at much lower doses, providing an important proof of concept milestone. Systematic efforts to improve the SHAM and AF scaffolds, aided with the elucidation of the TAO crystal structure, provided detailed structure-activity relationship information and reinvigorated the drug discovery effort. Recently, the coupling of mitochondrion-targeting lipophilic cations to TAO inhibitors has dramatically improved drug targeting and trypanocidal activity while retaining target protein potency. These developments appear to have finally signposted the way to preclinical development of TAO inhibitors.
Versión del editorhttp://dx.doi.org/10.1002/med.21560
URIhttp://hdl.handle.net/10261/176940
DOI10.1002/med.21560
Identificadoresdoi: 10.1002/med.21560
issn: 0198-6325
e-issn: 1098-1128
Aparece en las colecciones: (IQM) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

28
checked on 23-mar-2024

WEB OF SCIENCETM
Citations

23
checked on 26-feb-2024

Page view(s)

257
checked on 28-mar-2024

Download(s)

37
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.